|
gptkbp:instanceOf
|
gptkb:drug
antimuscarinic agent
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:ATCCode
|
G04BD08
|
|
gptkbp:brand
|
gptkb:Vesicare
|
|
gptkbp:CASNumber
|
242478-38-2
|
|
gptkbp:category
|
anticholinergic
spasmolytic
urinary antispasmodic
|
|
gptkbp:chemicalFormula
|
C23H26N2O2.C4H6O4
|
|
gptkbp:contraindication
|
urinary retention
uncontrolled narrow-angle glaucoma
gastric retention
|
|
gptkbp:developer
|
gptkb:Astellas_Pharma
|
|
gptkbp:eliminationHalfLife
|
45-68 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
solifenacin succinate
|
|
gptkbp:KEGGID
|
D08514
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
muscarinic receptor antagonist
|
|
gptkbp:MedlinePlusID
|
a604004
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
480.55 g/mol
|
|
gptkbp:patentExpired
|
2018 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
6918493
5293726
DB01591
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:routesOfElimination
|
renal
biliary
|
|
gptkbp:RxNorm
|
313343
|
|
gptkbp:sideEffect
|
constipation
blurred vision
dry mouth
urinary retention
|
|
gptkbp:UNII
|
8P7I9518TV
|
|
gptkbp:usedFor
|
urinary incontinence
overactive bladder
urinary frequency
urinary urgency
|
|
gptkbp:bfsParent
|
gptkb:solifenacin
|
|
gptkbp:bfsLayer
|
7
|